Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its ...
Houston, Texas, USA and Tuebingen, Germany, August 21, 2017 / B3C newswire / -- Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrolment of patients into a phase I trial of its first adoptive …